187 related articles for article (PubMed ID: 15321702)
21. Fusogenic peptide as diagnostic marker for detection of flaviviruses.
Pattnaik P; Srivastava A; Abhyankar A; Dash PK; Parida MM; Lakshmana Rao PV
J Postgrad Med; 2006; 52(3):174-8. PubMed ID: 16855316
[TBL] [Abstract][Full Text] [Related]
22. In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses.
Lo MK; Shi PY; Chen YL; Flint M; Spiropoulou CF
Antiviral Res; 2016 Jun; 130():46-9. PubMed ID: 27016316
[TBL] [Abstract][Full Text] [Related]
23. Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View.
Felicetti T; Manfroni G; Cecchetti V; Cannalire R
ChemMedChem; 2020 Dec; 15(24):2391-2419. PubMed ID: 32961008
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in flavivirus antiviral drug discovery and vaccine development.
Ray D; Shi PY
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):45-55. PubMed ID: 18221133
[TBL] [Abstract][Full Text] [Related]
25. Research on prevention and treatment of hemorrhagic fevers.
Joniec J; Kołodziej M; Bartoszcze M; Kocik J; Knap J
Ann Agric Environ Med; 2012; 19(2):165-71. PubMed ID: 22742784
[TBL] [Abstract][Full Text] [Related]
26. Treatment of yellow fever.
Monath TP
Antiviral Res; 2008 Apr; 78(1):116-24. PubMed ID: 18061688
[TBL] [Abstract][Full Text] [Related]
27. Molecular targets for flavivirus drug discovery.
Sampath A; Padmanabhan R
Antiviral Res; 2009 Jan; 81(1):6-15. PubMed ID: 18796313
[TBL] [Abstract][Full Text] [Related]
28. Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
Li PC; Jang J; Hsia CY; Groomes PV; Lian W; de Wispelaere M; Pitts JD; Wang J; Kwiatkowski N; Gray NS; Yang PL
ACS Infect Dis; 2019 Mar; 5(3):460-472. PubMed ID: 30608640
[TBL] [Abstract][Full Text] [Related]
29. The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system.
Clark DC; Brault AC; Hunsperger E
Arch Virol; 2012 Aug; 157(8):1423-40. PubMed ID: 22592957
[TBL] [Abstract][Full Text] [Related]
30. Review of Phytochemical Compounds as Antiviral Agents Against Arboviruses from the Genera Flavivirus and Alphavirus.
Sardari S; Rafieian-Kopaei M; Malekmohammad K; Sewell RDE
Curr Drug Discov Technol; 2020; 17(4):484-497. PubMed ID: 31969106
[TBL] [Abstract][Full Text] [Related]
31. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses.
Gowen BB; Holbrook MR
Antiviral Res; 2008 Apr; 78(1):79-90. PubMed ID: 18036672
[TBL] [Abstract][Full Text] [Related]
32. Prospects for antiviral therapy.
Leyssen P; Charlier N; Paeshuyse J; De Clercq E; Neyts J
Adv Virus Res; 2003; 61():511-53. PubMed ID: 14714442
[No Abstract] [Full Text] [Related]
33. Phosprenyl: a novel drug with antiviral and immunomodulatory activity.
Danilov LL; Maltsev SD; Deyeva AV; Narovlyansky AN; Sanin AV; Ozherelkov SV; Pronin AV
Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):395-400. PubMed ID: 9017158
[TBL] [Abstract][Full Text] [Related]
34. The importance of viral and cellular factors on flavivirus entry.
Cordero-Rivera CD; De Jesús-González LA; Osuna-Ramos JF; Palacios-Rápalo SN; Farfan-Morales CN; Reyes-Ruiz JM; Del Ángel RM
Curr Opin Virol; 2021 Aug; 49():164-175. PubMed ID: 34171540
[TBL] [Abstract][Full Text] [Related]
35. [Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
Wawrzynowicz-Syczewska M
Przegl Epidemiol; 2002; 56 Suppl 5():35-40. PubMed ID: 15553070
[TBL] [Abstract][Full Text] [Related]
36. Cellular Targets for the Treatment of Flavivirus Infections.
Zakaria MK; Carletti T; Marcello A
Front Cell Infect Microbiol; 2018; 8():398. PubMed ID: 30483483
[TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of highly pathogenic tick-borne flavivirus infection in the mouse model.
Tigabu B; Juelich T; Bertrand J; Holbrook MR
J Med Virol; 2009 Jul; 81(7):1261-9. PubMed ID: 19475605
[TBL] [Abstract][Full Text] [Related]
38. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses.
Crance JM; Scaramozzino N; Jouan A; Garin D
Antiviral Res; 2003 Mar; 58(1):73-9. PubMed ID: 12719009
[TBL] [Abstract][Full Text] [Related]
39. The flavivirus capsid protein: Structure, function and perspectives towards drug design.
Oliveira ERA; Mohana-Borges R; de Alencastro RB; Horta BAC
Virus Res; 2017 Jan; 227():115-123. PubMed ID: 27751882
[TBL] [Abstract][Full Text] [Related]
40. Animal models of viral hemorrhagic fever.
Smith DR; Holbrook MR; Gowen BB
Antiviral Res; 2014 Dec; 112():59-79. PubMed ID: 25448088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
